New immunotherapy combo shows promise for Tough-to-Treat lymphoma
NCT ID NCT05464329
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding the immunotherapy drug mosunetuzumab to standard chemotherapy can safely treat aggressive B-cell lymphoma that has come back or not responded to treatment. About 24 adults will receive either DHAX or ICE chemotherapy plus mosunetuzumab. The main goal is to check for side effects, but researchers will also look at how many patients achieve complete remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mosunetuzumab (an immunotherapy drug) combined with standard chemotherapy (DHAX or ICE)
What this could lead to
If successful, this could point toward a more effective treatment option for people with aggressive B-cell lymphoma that has come back or not responded to prior therapy.
What could go wrong
This is a very early (Phase 1) and small (24 participants) trial focused mainly on safety, not proof of effectiveness. The combination may cause significant side effects and may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States